The substantial reduction in risk of renal disease and major cardiovascular events seen with canagliflozin in patients with type 2 diabetes is likely to be a class effect of SGLT2 inhibitors, Australian study investigators say. A randomised controlled trial involving more than 4400 patients with type 2 diabetes and albuminuric chronic kidney disease found that ...
Renal and cardiovascular benefits are class effects of SGLT2 inhibitors: CREDENCE trial
By Michael Woodhead
24 Apr 2019